DekaBank Deutsche Girozentrale decreased its position in Pfizer, Inc. (NYSE:PFE) by 12.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,789,077 shares of the biopharmaceutical company’s stock after selling 684,033 shares during the period. Pfizer accounts for 1.3% of DekaBank Deutsche Girozentrale’s portfolio, making the stock its 7th largest position. DekaBank Deutsche Girozentrale owned 0.29% of Pfizer worth $161,739,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of PFE. Patton Albertson Miller Group LLC lifted its stake in Pfizer by 2.6% in the second quarter. Patton Albertson Miller Group LLC now owns 6,705 shares of the biopharmaceutical company’s stock valued at $222,000 after buying an additional 168 shares during the period. Granite Investment Advisors LLC lifted its stake in Pfizer by 3.3% in the second quarter. Granite Investment Advisors LLC now owns 8,635 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 277 shares during the period. Wedge Capital Management L L P NC acquired a new position in Pfizer in the second quarter valued at about $214,000. Crescent Grove Advisors LLC acquired a new position in Pfizer in the second quarter valued at about $1,060,000. Finally, Jones Collombin Investment Counsel Inc lifted its stake in Pfizer by 1.2% in the second quarter. Jones Collombin Investment Counsel Inc now owns 266,500 shares of the biopharmaceutical company’s stock valued at $8,952,000 after buying an additional 3,290 shares during the period. Institutional investors and hedge funds own 69.10% of the company’s stock.
In other news, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the transaction, the insider now directly owns 74,506 shares in the company, valued at approximately $2,436,346.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ian C. Read sold 197,168 shares of Pfizer stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the transaction, the chief executive officer now owns 580,318 shares of the company’s stock, valued at $19,730,812. The disclosure for this sale can be found here. Insiders have sold a total of 374,621 shares of company stock valued at $12,796,098 over the last quarter. 0.06% of the stock is currently owned by corporate insiders.
Several equities analysts have weighed in on PFE shares. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the company a “buy” rating in a research note on Monday, July 17th. BMO Capital Markets raised Pfizer from a “market perform” rating to an “outperform” rating and increased their target price for the company from $33.00 to $37.00 in a research note on Wednesday, August 2nd. UBS AG reaffirmed a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Finally, Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $38.48.
Pfizer, Inc. (NYSE PFE) opened at $35.18 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.34 and a quick ratio of 1.06. The firm has a market capitalization of $209,816.89, a P/E ratio of 14.08, a price-to-earnings-growth ratio of 2.49 and a beta of 1.01. Pfizer, Inc. has a one year low of $30.51 and a one year high of $36.78.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.67% and a net margin of 18.69%. The firm had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. During the same period last year, the company earned $0.61 earnings per share. The business’s revenue was up .9% compared to the same quarter last year. equities research analysts predict that Pfizer, Inc. will post 2.59 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.64%. Pfizer’s dividend payout ratio is currently 79.01%.
WARNING: “Pfizer, Inc. (PFE) Shares Sold by DekaBank Deutsche Girozentrale” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://sportsperspectives.com/2017/11/12/pfizer-inc-pfe-shares-sold-by-dekabank-deutsche-girozentrale.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.